Biological assessment of the virus-like drug conjugate AU-011 to specifically target a breadth of human cancer types
News Category: Presentations
ASCO GU 2022: Aura Preclinical Data Presented
Targeting urothelial neoplasia using an investigational virus-like drug conjugate
AAO 2021: Dr. Shields Presents Phase 1b/2 IVT AU-011 Data
A Phase 1b/2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Intravitreal Administration
AAO 2021: Dr. Demirci Presents Phase 2 SC AU-011 Data
A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration
ASRS 2021: Dr. Mruthyunjaya Presents Phase 2 AU-011 Data
A Phase 2 Trial of AU-011, an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration
Euretina 2021: Aura Clinical Data Presented
A Phase 2 Trial of AU-011for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma using Suprachoroidal Administration
ARVO 2021: Aura Clinical Data Presented
ARVO 2021: Aura Preclinical Data Presented
AAO 2020: Dr. Carol Shields Presents Overview of AU-011
AU-011, a Targeted Therapy for Primary Treatment of Choroidal Melanoma (CM) via Intravitreal (IVT) or Suprachoroidal (SC) Administration